Celltrion’s Remsima receives ‘approval recommendation’ for all indications
On the 9th of February(local time), Celltrion announced the first biosimilar antibody, ‘Remsima,’ received ‘approval recommendation’ for all the indications applied from the U.S. Food and Drug Administration(FDA) Arthritis Advisory Committee, like its original drug.
At the meeting held at the FD...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
